AIM ImmunoTech Inc. 宣布,其评估Ampligen®联合阿斯利康Imfinzi®用于治疗胰腺癌的II期研究,在年终时取得了积极的中期临床进展。
AIM ImmunoTech Inc. 宣布,其评估Ampligen®联合阿斯利康Imfinzi®用于治疗胰腺癌的II期研究,在年终时取得了积极的中期临床进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.